Thymosin α1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance

被引:152
作者
Romani, Luigina
Bistoni, Francesco
Perruccio, Katia
Montagnoli, Claudia
Gaziano, Roberta
Bozza, Silvia
Bonifazi, Pierluigi
Bistoni, Giovanni
Rasi, Guido
Velardi, Andrea
Fallarino, Francesca
Garaci, Enrico
Puccetti, Paolo
机构
[1] Univ Perugia, Microbiol Sect, Dept Expt Med, I-06126 Perugia, Italy
[2] Univ Perugia, Dept Biochem Sci, I-06126 Perugia, Italy
[3] Univ Perugia, Div Hematol & Clin Immunol, Dept Clin & Expt Med, Perugia, Italy
[4] CNR, Inst Neurobiol & Mol Med, Rome, Italy
[5] NIH, Rome, Italy
关键词
D O I
10.1182/blood-2006-02-004762
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thymosin alpha 1 (T alpha 1), a naturally occurring thymic peptide, primes dendritic cells (DCs) for antifungal T-helper type 1 resistance through Toll-like receptor 9 (TLR9) signaling. As TLR9 signaling also activates the immuno-suppressive pathway of tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO), we examined T alpha 1 for possible induction of DC-dependent regulatory effects. T alpha 1 affected T-helper cell priming and tolerance induction by human and murine DCs and induced IDO expression and function in the latter cells. IDO activation by T alpha 1 required TLR9 and type 1 interferon receptor signaling and resulted in interleukin-10 production and generation of regulatory T cells. In transfer experiments, functionally distinct subsets of differentiated DCs were required for priming and tolerance to a fungal pathogen or alloantigens. In contrast, T alpha 1-primed DCs fulfilled multiple requirements, including the induction of T-helper type 1 immunity within a regulatory environment. Thus, instructive immunotherapy with T alpha 1 targeting IDO-competent DCs could allow for a balanced control of inflammation and tolerance.
引用
收藏
页码:2265 / 2274
页数:10
相关论文
共 46 条
[41]   In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes [J].
Tang, QZ ;
Henriksen, KJ ;
Bi, MY ;
Finger, EB ;
Szot, G ;
Ye, JQ ;
Masteller, EL ;
McDevitt, H ;
Bonyhadi, M ;
Bluestone, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (11) :1455-1465
[42]   CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade [J].
Taylor, PA ;
Noelle, RJ ;
Blazar, BR .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (11) :1311-1317
[43]   Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia [J].
Trenado, A ;
Charlotte, F ;
Fisson, S ;
Yagello, M ;
Klatzmann, D ;
Salomon, BL ;
Cohen, AL .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (11) :1688-1696
[44]   Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow [J].
Ueda, Y ;
Kondo, M ;
Kelsoe, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (11) :1771-1780
[45]   Differential signaling by CpG DNA in DCs and B cells: not just TLR9 [J].
Verthelyi, D ;
Zeuner, RA .
TRENDS IN IMMUNOLOGY, 2003, 24 (10) :519-522
[46]  
Weigel BJ, 2002, BLOOD, V100, P4169, DOI 10.1182/blood-2002-04-1063